John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at jparkinson@mjhlifesciences.com.
Honoring Her Daughter’s Legacy After a Long-Standing Battle With Antimicrobial Resistance
September 5th 2024After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.
Read More
Monoclonal Antibody Reduces Symptomatic COVID-19 Risk by 84% in Immunocompromised
Published: August 27th 2024 | Updated: August 27th 2024Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.
Read More
The Benefits of Making C diff a Nationally Notifiable Infectious Disease
August 26th 2024In the second part of our interview with Christian Lillis, cofounder and CEO of the Peggy Lillis Foundation, he discusses what the passage of the Peggy Lillis Clostridioides difficile Inclusion Act would do for reporting of the infection as well as the potential ancillary effects around antibiotic development and antimicrobial resistance.
Read More
Mpox Vaccine Manufacturer is Prepared to Increase Production
August 19th 2024Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.
Read More
The Significance of WHO Declaring Mpox a Global Emergency
August 16th 2024Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.
Read More
Mpox and Concerns Around the Disease in the United States
August 15th 2024Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.
Read More
The Genesis of C diff Advocacy
August 13th 2024Peggy Lillis Foundation CEO Christian Lillis talks about how he became involved in advocacy around C diff and his motivation in helping to bring a bill to Congress to make the healthcare-associated infection a nationally notifiable infectious disease and condition.
Read More
A War Zone and its Increasing Infectious Disease Toll
August 12th 2024With the ongoing war between Israel and Hamas, The World Health Organization reported a public health update. Officials are concerned about what is happening inside the Gaza Strip particularly around a variety of diseases and health conditions including hepatitis A, skin infections, and even polio.
Read More
Providers May Need to Tailor Prescribing Based on Local Trends in Staphylococcus aureus Resistance
August 9th 2024A large Veterans Health Administration (VA) outpatient study showed a large increase in MRSA resistance in one particular area of the United States and varying antimicrobial resistance patterns overall.
Read More
Could a Nasal COVID-19 Vaccine Offer Differing Benefits to Subcutaneous Injections?
August 8th 2024A new phase 1 clinical trial will determine if vaccine candidate, MPV/S-2P, is safe for humans, and may potentially offer protection not seen before in the first-generation of COVID-19 vaccines.
Read More
CDC Provides Additional Data on RSV Vaccines’ Safety, Rationale on Recommendations
August 7th 2024In this week’s edition of MMWR, the Centers for Disease Control and Prevention reported on the vaccines’ safety profile for each of the FDA approved immunizations and rationale for the recommended age groups.
Read More
WHO: Prepare to Identify Hypervirulent Pathogen
Published: August 5th 2024 | Updated: August 5th 2024The World Health Organization (WHO) warns of a moderate global risk to the presence of the pathogen, hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23, as it has been reported in at least 1 country in all 6 WHO Regions.
Read More